Thu. 21 Mar 2024, 7:20am ET
Benzinga
Earnings, News
aMilestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 3.23 percent decrease over losses of $(0.31) per share from the same period last year.